{
  "document": "Foundation_21",
  "Genomic Findings": [
    {
      "Name": "PDCD1LG2 (PD-L2) amplification",
      "Clinical": [
        "Atezolizumab",
        "Cemiplimab",
        "Durvalumab",
        "Nivolumab",
        "Pembrolizumab",
        "Dostarlimab"
      ],
      "No Clinical": ["Avelumab"]
    },
    {
      "Name": "MET exon 14 splice site (2888-1G>C) amplification",
      "Clinical": ["Capmatinib", "Crizotinib", "Tepotinib"],
      "No Clinical": ["Cabozantinib"]
    },
    {
      "Name": "ATM R337H",
      "Clinical": [],
      "No Clinical": ["Niraparib", "Olaparib", "Rucaparib", "Talazoparib"]
    },
    { "Name": "CDK4 amplification", "Clinical": [], "No Clinical": [] },
    { "Name": "CDK6 amplification", "Clinical": [], "No Clinical": [] },
    { "Name": "MDM2 amplification", "Clinical": [], "No Clinical": [] },
    {
      "Name": "CDKN2A/B p16INK4a loss and p14ARF loss exons 2-3",
      "Clinical": [],
      "No Clinical": []
    },
    { "Name": "EPHB4 amplification", "Clinical": [], "No Clinical": [] },
    { "Name": "ERBB3 amplification", "Clinical": [], "No Clinical": [] },
    { "Name": "JAK2 amplification", "Clinical": [], "No Clinical": [] }
  ],
  "Biomakers findings": [
    {
      "Name": "Microsatellite status - MS-Stable",
      "Clinical": [],
      "No Clinical": []
    },
    {
      "Name": "Tumor Mutational Burden - 9 Muts/Mb",
      "Clinical": [],
      "No Clinical": []
    }
  ]
}
